{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:50:41Z","timestamp":1792763441063,"version":"4.5.0"},"reference-count":170,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.phrs.2025.107983","type":"journal-article","created":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:26:20Z","timestamp":1760145980000},"page":"107983","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Vascular endothelial cells and angiogenesis"],"prefix":"10.1016","volume":"221","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9861-4139","authenticated-orcid":false,"suffix":"Jr.","given":"Robert","family":"Roskoski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2025.107983_bib1","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s10238-025-01633-y","article-title":"A darwinian approach to the development of the vascular system in the vertebrates","volume":"25","author":"Ribatti","year":"2025","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.phrs.2025.107983_bib2","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.critrevonc.2007.01.006","article-title":"Vascular endothelial growth factor (VEGF) signaling in tumor progression","volume":"62","author":"Roskoski","year":"2007","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.phrs.2025.107983_bib3","first-page":"3527","article-title":"Endothelial cells in physiology and in the pathophysiology of vascular disorders","volume":"91","author":"Cines","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2025.107983_bib4","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/s41580-023-00631-w","article-title":"Biology and therapeutic targeting of vascular endothelial growth factor A","volume":"24","author":"P\u00e9rez-Guti\u00e9rrez","year":"2023","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.phrs.2025.107983_bib5","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1161\/01.ATV.17.4.605","article-title":"Manipulating angiogenesis. From basic science to the bedside","volume":"17","author":"Pepper","year":"1997","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.phrs.2025.107983_bib6","doi-asserted-by":"crossref","DOI":"10.1089\/ten.teb.2024.0242","article-title":"Surgical bioengineering of the microvasculature and challenges in clinical translation","author":"Schlidt","year":"2025","journal-title":"Tissue Eng. Part B Rev."},{"key":"10.1016\/j.phrs.2025.107983_bib7","doi-asserted-by":"crossref","first-page":"1359069","DOI":"10.3389\/fonc.2024.1359069","article-title":"Mechanisms of angiogenesis in tumour","volume":"14","author":"Zhang","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.phrs.2025.107983_bib8","doi-asserted-by":"crossref","first-page":"14608","DOI":"10.1073\/pnas.97.26.14608","article-title":"Mosaic blood vessels in tumors: frequency of cancer cells in contact with flowing blood","volume":"97","author":"Chang","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2025.107983_bib9","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0002-9440(10)65173-5","article-title":"Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry","volume":"155","author":"Maniotis","year":"1999","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.phrs.2025.107983_bib10","doi-asserted-by":"crossref","first-page":"756","DOI":"10.3390\/biology14070756","article-title":"Role and mechanisms of angiogenesis in tumours","volume":"14","author":"Sobczy\u0144ska-Rak","year":"2025","journal-title":"Biology"},{"issue":"3","key":"10.1016\/j.phrs.2025.107983_bib11","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.bbrc.2008.07.121","article-title":"VEGF receptor protein-tyrosine kinases: structure and regulation","volume":"375","author":"Roskoski","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2025.107983_bib12","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.3390\/ijms20092067","article-title":"Alternative splicing in angiogenesis","volume":"20","author":"Bowler","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2025.107983_bib13","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1083\/jcb.67.3.835","article-title":"Transfer of proteins across membranes. I. presence of proteolytically processed and unprocessed nascent immunoglobulin light chains on membrane-bound ribosomes of murine myeloma","volume":"67","author":"Blobel","year":"1975","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.phrs.2025.107983_bib14","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/bs.ctdb.2016.10.001","article-title":"VEGF receptor tyrosine kinases: key regulators of vascular function","volume":"123","author":"\u00c1lvarez-Aznar","year":"2017","journal-title":"Curr. Top. Dev. Biol."},{"key":"10.1016\/j.phrs.2025.107983_bib15","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1146\/annurev.bi.62.070193.002321","article-title":"Signalling by receptor tyrosine kinases","volume":"62","author":"Fantl","year":"1993","journal-title":"Annu Rev. Biochem."},{"key":"10.1016\/j.phrs.2025.107983_bib16","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","article-title":"Cell signaling by receptor tyrosine kinases","volume":"141","author":"Lemmon","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2025.107983_bib17","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1126\/science.1075762","article-title":"The protein kinase complement of the human genome","volume":"298","author":"Manning","year":"2002","journal-title":"Science"},{"key":"10.1016\/j.phrs.2025.107983_bib18","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1126\/science.2479986","article-title":"Vascular endothelial growth factor is a secreted angiogenic mitogen","volume":"246","author":"Leung","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.phrs.2025.107983_bib19","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1126\/science.2479987","article-title":"Vascular permeability factor, an endothelial cell mitogen related to PDGF","volume":"246","author":"Keck","year":"1989","journal-title":"Science"},{"key":"10.1016\/j.phrs.2025.107983_bib20","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1210\/edrv.18.1.0287","article-title":"The biology of vascular endothelial growth factor","volume":"18","author":"Ferrara","year":"1997","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.phrs.2025.107983_bib21","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/380435a0","article-title":"Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele","volume":"380","author":"Carmeliet","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2025.107983_bib22","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/380439a0","article-title":"Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene","volume":"380","author":"Ferrara","year":"1996","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2025.107983_bib23","doi-asserted-by":"crossref","first-page":"7192","DOI":"10.1073\/pnas.94.14.7192","article-title":"Vascular endothelial growth factor: crystal structure and functional mapping of the kinase domain receptor binding site","volume":"94","author":"Muller","year":"1997","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2025.107983_bib24","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3389\/fcvm.2018.00039","article-title":"Vascular endothelial growth factor B and its signaling","volume":"5","author":"Lal","year":"2018","journal-title":"Front. Cardiovasc. Med."},{"key":"10.1016\/j.phrs.2025.107983_bib25","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jmb.2006.03.002","article-title":"Crystal structure of human vascular endothelial growth factor-B: identification of amino acids important for receptor binding","volume":"359","author":"Iyer","year":"2006","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.phrs.2025.107983_bib26","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0167-4781(98)00040-2","article-title":"A comparative study of the expression patterns for vegf, vegf-b\/vfr,\u00a0and\u00a0vegf-c in the developing and adult mouse","volume":"1398","author":"Lagercrantz","year":"1998","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.phrs.2025.107983_bib27","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0002-9440(10)65550-2","article-title":"Vascular endothelial growth factors VEGF-B and VEGF-C are expressed in human tumors","volume":"153","author":"Salven","year":"1998","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.phrs.2025.107983_bib28","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1161\/01.CIR.104.3.358","article-title":"Vascular endothelial growth factor-B-deficient mice display an atrial conduction defect","volume":"104","author":"Aase","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.phrs.2025.107983_bib29","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/j.1460-2075.1996.tb00521.x","article-title":"A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases","volume":"15","author":"Joukov","year":"1996","journal-title":"EMBO J."},{"key":"10.1016\/j.phrs.2025.107983_bib30","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1093\/emboj\/16.13.3898","article-title":"Proteolytic processing regulates receptor specificity and activity of VEGF-C","volume":"16","author":"Joukov","year":"1997","journal-title":"EMBO J."},{"key":"10.1016\/j.phrs.2025.107983_bib31","doi-asserted-by":"crossref","first-page":"25176","DOI":"10.1074\/jbc.272.40.25176","article-title":"Genomic organization of human and mouse genes for vascular endothelial growth factor C","volume":"272","author":"Chilov","year":"1997","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2025.107983_bib32","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1242\/dev.122.12.3829","article-title":"VEGF-C receptor binding and pattern of expression with VEGFR-3 suggests a role in lymphatic vascular development","volume":"122","author":"Kukk","year":"1996","journal-title":"Development"},{"key":"10.1016\/j.phrs.2025.107983_bib33","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1161\/01.RES.85.11.992","article-title":"Vascular endothelial growth factor (VEGF) and VEGF-C show overlapping binding sites in embryonic endothelia and distinct sites in differentiated adult endothelia","volume":"85","author":"Lymboussaki","year":"1999","journal-title":"Circ. Res."},{"key":"10.1016\/j.phrs.2025.107983_bib34","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ccr.2006.02.018","article-title":"The VEGF-C\/Flt-4 axis promotes invasion and metastasis of cancer cells","volume":"9","author":"Su","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.phrs.2025.107983_bib35","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s10147-005-0528-3","article-title":"Expression of vascular endothelial growth factor (VEGF)-C and -D in gastric carcinoma","volume":"11","author":"Shida","year":"2006","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2025.107983_bib36","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/ni1013","article-title":"Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins","volume":"5","author":"Karkkainen","year":"2004","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.phrs.2025.107983_bib37","doi-asserted-by":"crossref","first-page":"32127","DOI":"10.1074\/jbc.274.45.32127","article-title":"Biosynthesis of vascular endothelial growth factor-D involves proteolytic processing which generates non-covalent homodimers","volume":"274","author":"Stacker","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2025.107983_bib38","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1096\/fj.05-5646com","article-title":"Functional interaction of VEGF-C and VEGF-D with neuropilin receptors","volume":"20","author":"K\u00e4rp\u00e4nen","year":"2006","journal-title":"FASEB J."},{"key":"10.1016\/j.phrs.2025.107983_bib39","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1006\/geno.1997.4774","article-title":"Molecular cloning of a novel vascular endothelial growth factor, VEGF-D","volume":"42","author":"Yamada","year":"1997","journal-title":"Genomics"},{"key":"10.1016\/j.phrs.2025.107983_bib40","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1006\/geno.1997.5079","article-title":"Human FIGF: cloning, gene structure, and mapping to chromosome Xp22.1 between the PIGA and the GRPR genes","volume":"47","author":"Rocchigiani","year":"1998","journal-title":"Genomics"},{"key":"10.1016\/j.phrs.2025.107983_bib41","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1128\/MCB.25.6.2441-2449.2005","article-title":"Vascular endothelial growth factor D is dispensable for development of the lymphatic system","volume":"25","author":"Baldwin","year":"2005","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.phrs.2025.107983_bib42","doi-asserted-by":"crossref","first-page":"12153","DOI":"10.1074\/jbc.M008055200","article-title":"The crystal structure of human placenta growth factor-1 (PlGF-1), an angiogenic protein, at 2.0 \u00b0A resolution","volume":"276","author":"Iyer","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2025.107983_bib43","first-page":"925","article-title":"Two alternative mRNAs coding for the angiogenic factor, placenta growth factor (PlGF), are transcribed from a single gene of chromosome 14","volume":"8","author":"Maglione","year":"1993","journal-title":"Oncogene"},{"key":"10.1016\/j.phrs.2025.107983_bib44","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1006\/bbrc.1997.6813","article-title":"Placenta growth factor: identification and characterization of a novel isoform generated by RNA alternative splicing","volume":"235","author":"Cao","year":"1997","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2025.107983_bib45","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1093\/emboj\/18.2.363","article-title":"A novel vascular endothelial growth factor encoded by orf virus, VEGF-E, mediates angiogenesis via signaling through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) receptor tyrosine kinases","volume":"18","author":"Meyer","year":"1999","journal-title":"EMBO J."},{"key":"10.1016\/j.phrs.2025.107983_bib46","doi-asserted-by":"crossref","first-page":"26988","DOI":"10.1016\/S0021-9258(18)47116-5","article-title":"Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor","volume":"269","author":"Waltenberger","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2025.107983_bib47","doi-asserted-by":"crossref","first-page":"11709","DOI":"10.1073\/pnas.95.20.11709","article-title":"Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells","volume":"95","author":"Olofsson","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2025.107983_bib48","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1126\/science.1312256","article-title":"The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor","volume":"255","author":"de Vries","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.phrs.2025.107983_bib49","doi-asserted-by":"crossref","first-page":"8915","DOI":"10.1073\/pnas.90.19.8915","article-title":"Vascular endothelial growth factor receptor expression during embryogenesis and tissue repair suggests a role in endothelial differentiation and blood vessel growth","volume":"90","author":"Peters","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2025.107983_bib50","doi-asserted-by":"crossref","first-page":"7533","DOI":"10.1073\/pnas.90.16.7533","article-title":"Fetal liver kinase 1 is a receptor for vascular endothelial growth factor and is selectively expressed in vascular endothelium","volume":"90","author":"Quinn","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2025.107983_bib51","doi-asserted-by":"crossref","first-page":"10705","DOI":"10.1073\/pnas.90.22.10705","article-title":"Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor","volume":"90","author":"Kendall","year":"1993","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2025.107983_bib52","doi-asserted-by":"crossref","first-page":"3336","DOI":"10.1182\/blood.V87.8.3336.bloodjournal8783336","article-title":"Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1","volume":"87","author":"Barleon","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2025.107983_bib53","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1006\/bbrc.1996.1355","article-title":"Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR","volume":"226","author":"Kendall","year":"1996","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2025.107983_bib54","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1095\/biolreprod59.6.1540","article-title":"A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation","volume":"59","author":"Clark","year":"1998","journal-title":"Biol. Reprod."},{"key":"10.1016\/j.phrs.2025.107983_bib55","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ajog.2005.12.049","article-title":"Evaluation of placenta growth factor and soluble Fms-like tyrosine kinase 1 receptor levels in mild and severe preeclampsia","volume":"195","author":"Robinson","year":"2006","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.phrs.2025.107983_bib56","doi-asserted-by":"crossref","first-page":"25646","DOI":"10.1016\/S0021-9258(18)47298-5","article-title":"Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1\/KDR","volume":"269","author":"Park","year":"1994","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2025.107983_bib57","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.phrs.2017.03.010","article-title":"Vascular endothelial growth factor (VEGF) and VEGF receptor inhibitors in the treatment of renal cell carcinomas","volume":"120","author":"Roskoski","year":"2017","journal-title":"Pharm. Res"},{"key":"10.1016\/j.phrs.2025.107983_bib58","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.str.2016.12.012","article-title":"Structure of the full-length VEGFR-1 extracellular domain in complex with VEGF-A","volume":"25","author":"Markovic-Mueller","year":"2017","journal-title":"Structure"},{"key":"10.1016\/j.phrs.2025.107983_bib59","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1182\/blood-2011-11-390922","article-title":"Thermodynamic and structural description of allosterically regulated VEGFR-2 dimerization","volume":"119","author":"Brozzo","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2025.107983_bib60","doi-asserted-by":"crossref","first-page":"12960","DOI":"10.1073\/pnas.1301415110","article-title":"Structural and mechanistic insights into VEGF receptor 3 ligand binding and activation","volume":"110","author":"Lepp\u00e4nen","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2025.107983_bib61","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1006\/bbrc.1997.7327","article-title":"The phosphorylated 1169-tyrosine containing region of flt-1 kinase (VEGFR-1) is a major binding site for PLC\u03b3","volume":"238","author":"Sawano","year":"1997","journal-title":"Biochem. Biophys. Re.s Commun."},{"key":"10.1016\/j.phrs.2025.107983_bib62","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nrm1911","article-title":"VEGFreceptor signalling\u2014in control of vascular function","volume":"7","author":"Olsson","year":"2006","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.phrs.2025.107983_bib63","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/nm884","article-title":"Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1","volume":"9","author":"Autiero","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2025.107983_bib64","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0092-8674(00)80456-0","article-title":"Crystal structure at 1.7A resolution of VEGF in complex with domain 2 of the Flt-1 receptor","volume":"91","author":"Wiesmann","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2025.107983_bib65","doi-asserted-by":"crossref","first-page":"10382","DOI":"10.1074\/jbc.M313237200","article-title":"The crystal structure of placental growth factor in complex with domain 2 of vascular endothelial growth factor receptor-1","volume":"279","author":"Christinger","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2025.107983_bib66","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1074\/jbc.M002016200","article-title":"Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2)","volume":"276","author":"Gille","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2025.107983_bib67","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/emboj\/20.11.2768","article-title":"A single autophosphorylation site on KDR\/Flk-1 is essential for VEGF-A\u2013dependent activation of PLC-\u03b3 and DNA synthesis in vascular endothelial cells","volume":"20","author":"Takahashi","year":"2001","journal-title":"EMBO J."},{"key":"10.1016\/j.phrs.2025.107983_bib68","doi-asserted-by":"crossref","first-page":"31047","DOI":"10.1074\/jbc.274.43.31047","article-title":"Vascular endothelial growth factor effect on endothelial cell proliferation, migration, and platelet-activating factor synthesis is Flk-1-dependent","volume":"274","author":"Bernatchez","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2025.107983_bib69","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1038\/sj.emboj.7600709","article-title":"VEGF receptor-2 Y951 signaling and a role for the adapter molecule TSAd in tumor angiogenesis","volume":"24","author":"Matsumoto","year":"2005","journal-title":"EMBO J."},{"key":"10.1016\/j.phrs.2025.107983_bib70","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.yexcr.2005.11.012","article-title":"Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis","volume":"312","author":"Shibuya","year":"2006","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.phrs.2025.107983_bib71","doi-asserted-by":"crossref","first-page":"6453","DOI":"10.1074\/jbc.274.10.6453","article-title":"Vascular endothelial growth factor receptor KDR tyrosine kinase activity is increased by autophosphorylation of two activation loop tyrosine residues","volume":"274","author":"Kendall","year":"1999","journal-title":"J. Biol. Chem."},{"issue":"20","key":"10.1016\/j.phrs.2025.107983_bib72","doi-asserted-by":"crossref","DOI":"10.1172\/JCI161366","article-title":"Endothelial VEGFR2-PLC\u03b3 signaling regulates vascular permeability and antitumor immunity through eNOS\/Src","volume":"133","author":"Sj\u00f6berg","year":"2023","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.phrs.2025.107983_bib73","doi-asserted-by":"crossref","first-page":"22267","DOI":"10.1074\/jbc.M312729200","article-title":"The adaptor protein Shb binds to tyrosine 1175 in vascular endothelial growth factor (VEGF) receptor-2 and regulates VEGF-dependent cellular migration","volume":"279","author":"Holmqvist","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2025.107983_bib74","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/nm884","article-title":"Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1","volume":"9","author":"Autiero","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2025.107983_bib75","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1158\/1541-7786.315.2.6","article-title":"A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma","volume":"2","author":"Ebos","year":"2004","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.phrs.2025.107983_bib76","doi-asserted-by":"crossref","first-page":"4187","DOI":"10.1002\/ehf2.13555","article-title":"PREHOSP-CHF study investigators. Soluble vascular endothelial growth factor receptor 2 and prognosis in patients with chronic heart failure","volume":"8","author":"Iguchi","year":"2021","journal-title":"ESC Heart Fail."},{"key":"10.1016\/j.phrs.2025.107983_bib77","first-page":"5738","article-title":"FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines","volume":"52","author":"Pajusola","year":"1992","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2025.107983_bib78","first-page":"1233","article-title":"The FLT4 gene encodes a transmembrane tyrosine kinase related to the vascular endothelial growth factor receptor","volume":"8","author":"Galland","year":"1993","journal-title":"Oncogene"},{"key":"10.1016\/j.phrs.2025.107983_bib79","doi-asserted-by":"crossref","first-page":"3566","DOI":"10.1073\/pnas.92.8.3566","article-title":"Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development","volume":"92","author":"Kaipainen","year":"1995","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2025.107983_bib80","doi-asserted-by":"crossref","first-page":"40973","DOI":"10.1074\/jbc.M304499200","article-title":"Ligand-induced vascular endothelial growth factor receptor-3 (VEGFR-3) heterodimerization with VEGFR-2 in primary lymphatic endothelial cells regulates tyrosine phosphorylation sites","volume":"278","author":"Dixelius","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2025.107983_bib81","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.bbrc.2004.08.237","article-title":"Heterodimerization with vascular endothelial growth factor receptor-2 (VEGFR-2) is necessary for VEGFR-3 activity","volume":"324","author":"Alam","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.phrs.2025.107983_bib82","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0092-8674(00)81402-6","article-title":"Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor","volume":"92","author":"Soker","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2025.107983_bib83","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/0896-6273(91)90268-5","article-title":"The A5 antigen, a candidate for the neuronal recognition molecule, has homologies to complement components and coagulation factors","volume":"7","author":"Takagi","year":"1991","journal-title":"Neuron"},{"key":"10.1016\/j.phrs.2025.107983_bib84","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0896-6273(00)80870-3","article-title":"Neuropilin-2 regulates the development of selective cranial and sensory nerves and hippocampal mossy fiber projections","volume":"25","author":"Chen","year":"2000","journal-title":"Neuron"},{"key":"10.1016\/j.phrs.2025.107983_bib85","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.yexcr.2005.11.024","article-title":"Neuropilins in neoplasms: expression, regulation, and function","volume":"312","author":"Bielenberg","year":"2006","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.phrs.2025.107983_bib86","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1158\/1535-7163.MCT-05-0538","article-title":"The role of neuropilins in cancer","volume":"5","author":"Ellis","year":"2006","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.phrs.2025.107983_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217308","article-title":"Role of semaphorins, neuropilins and plexins in cancer progression","volume":"606","author":"Fern\u00e1ndez-Nogueira","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.phrs.2025.107983_bib88","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3389\/fimmu.2020.00346","article-title":"Semaphorins in angiogenesis and autoimmune diseases: therapeutic targets","volume":"11","author":"Iragavarapu-Charyulu","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phrs.2025.107983_bib89","doi-asserted-by":"crossref","first-page":"8609","DOI":"10.1016\/S0021-9258(17)34336-3","article-title":"Isolation and characterization of a high molecular weight glycoprotein from human blood vessels","volume":"253","author":"Lawler","year":"1978","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2025.107983_bib90","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3390\/curroncol32040203","article-title":"Neuropilin-1: a multifaceted target for cancer therapy","volume":"32","author":"Varanasi","year":"2025","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.phrs.2025.107983_bib91","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/S0092-8674(00)80766-7","article-title":"Unified nomenclature for the semaphorins\/collapsins","volume":"97","author":"Semaphorin nomenclature committee","year":"1999","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2025.107983_bib92","doi-asserted-by":"crossref","unstructured":"Guttmann-Raviv N., Kessler O., Shraga-Heled N., Lange T., Herzog Y., Neufeld G. The neuropilins and their role in tumorigenesis and tumor progression, Cancer Lett. 2006;231:1\u201311. doi: 10.1016\/j.canlet.2004.12.047.","DOI":"10.1016\/j.canlet.2004.12.047"},{"key":"10.1016\/j.phrs.2025.107983_bib93","doi-asserted-by":"crossref","first-page":"22272","DOI":"10.1074\/jbc.273.35.22272","article-title":"Neuropilin-1 is a placenta growth factor-2 receptor","volume":"273","author":"Migdal","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2025.107983_bib94","doi-asserted-by":"crossref","first-page":"21217","DOI":"10.1074\/jbc.274.30.21217","article-title":"Differential binding of vascular endothelial growth factor B splice and proteolytic isoforms to neuropilin-1","volume":"274","author":"Makinen","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2025.107983_bib95","doi-asserted-by":"crossref","first-page":"18040","DOI":"10.1074\/jbc.M909259199","article-title":"Neuropilin-2 is a receptor for the vascular endothelial growth factor (VEGF) forms VEGF-145 and VEGF-165","volume":"275","author":"Gluzman-Poltorak","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2025.107983_bib96","doi-asserted-by":"crossref","first-page":"12677","DOI":"10.1073\/pnas.221449198","article-title":"A model for gene therapy of human hereditary lymphedema","volume":"98","author":"Karkkainen","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2025.107983_bib97","doi-asserted-by":"crossref","DOI":"10.1002\/pro.4452","article-title":"Hybrid in vitro\/in silico analysis of low-affinity protein-protein interactions that regulate signal transduction by Sema6D","volume":"31","author":"Tanaka","year":"2022","journal-title":"Protein Sci."},{"key":"10.1016\/j.phrs.2025.107983_bib98","doi-asserted-by":"crossref","first-page":"24818","DOI":"10.1074\/jbc.M200730200","article-title":"Neuropilin-1 binds vascular endothelial growth factor 165, placenta growth factor-2, and heparin via its b1b2 domain","volume":"277","author":"Mamluk","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2025.107983_bib99","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/2203","article-title":"Semaphorins A and E act as antagonists of neuropilin-1 and agonists of neuropilin-2 receptors","volume":"1","author":"Takahashi","year":"1998","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.phrs.2025.107983_bib100","doi-asserted-by":"crossref","first-page":"8402","DOI":"10.3390\/ijms23158402","article-title":"Neuropilin (NRPs) related pathological conditions and their modulators","volume":"23","author":"Broz","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2025.107983_bib101","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1182\/blood-2005-11-4447","article-title":"Neuropilin-2 interacts with VEGFR-2 and VEGFR-3 and promotes human endothelial cell survival and migration","volume":"108","author":"Favier","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2025.107983_bib102","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1096\/fj.00-0250com","article-title":"Neuropilin-1 expression by tumor cells promotes tumor angiogenesis and progression","volume":"14","author":"Miao","year":"2000","journal-title":"FASEB J."},{"key":"10.1016\/j.phrs.2025.107983_bib103","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1016\/S0002-9440(10)63772-8","article-title":"Neuropilin-1 in human colon cancer: expression, regulation, and role in induction of angiogenesis","volume":"164","author":"Parikh","year":"2004","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.phrs.2025.107983_bib104","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/sj.bjc.6602663","article-title":"Overexpression of neuropilin-1 promotes constitutive MAPK signalling and chemoresistance in pancreatic cancer cells","volume":"93","author":"Wey","year":"2005","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.phrs.2025.107983_bib105","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1159\/000055854","article-title":"Pancreatic cancer: factors regulating tumor development, maintenance and metastasis","volume":"1","author":"Shi","year":"2001","journal-title":"Pancreatology"},{"key":"10.1016\/j.phrs.2025.107983_bib106","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/sj.bjc.6602308","article-title":"A peptide corresponding to the neuropilin-1-binding site on VEGF(165) induces apoptosis of neuropilin-1-expressing breast tumour cells","volume":"92","author":"Barr","year":"2005","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.phrs.2025.107983_bib107","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1476-5586(03)80020-9","article-title":"Semaphorin SEMA3F and VEGF have opposing effects on cell attachment and spreading","volume":"5","author":"Nasarre","year":"2003","journal-title":"Neoplasia"},{"key":"10.1016\/j.phrs.2025.107983_bib108","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1593\/neo.04481","article-title":"Semaphorin SEMA3F has a repulsing activity on breast cancer cells and inhibits E-cadherin-mediated cell adhesion","volume":"7","author":"Nasarre","year":"2005","journal-title":"Neoplasia"},{"key":"10.1016\/j.phrs.2025.107983_bib109","first-page":"1289","article-title":"Distinct 3p21.3 deletions in lung cancer and identification of a new human semaphorin","volume":"12","author":"Roche","year":"1996","journal-title":"Oncogene"},{"key":"10.1016\/j.phrs.2025.107983_bib110","doi-asserted-by":"crossref","first-page":"4120","DOI":"10.1073\/pnas.93.9.4120","article-title":"Human semaphorins A (V) and IV reside in the 3p21.3 small cell lung cancer deletion region and demonstrate distinct expression patterns","volume":"93","author":"Sekido","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2025.107983_bib111","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1006\/geno.1996.0074","article-title":"Isolation of the human semaphorin III\/F gene (SEMA3F) at chromosome 3p21, a region deleted in lung cancer","volume":"32","author":"Xiang","year":"1996","journal-title":"Genomics"},{"key":"10.1016\/j.phrs.2025.107983_bib112","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1593\/neo.04721","article-title":"Selective suppression of in vivo tumorigenicity by semaphorin SEMA3F in lung cancer cells","volume":"7","author":"Kusy","year":"2005","journal-title":"Neoplasia"},{"key":"10.1016\/j.phrs.2025.107983_bib113","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1158\/0008-5472.CAN-03-3090","article-title":"Semaphorin-3F is an inhibitor of tumor angiogenesis","volume":"64","author":"Kessler","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2025.107983_bib114","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1073\/pnas.040337597","article-title":"Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: in vivo expression and antitumor activity","volume":"97","author":"Gagnon","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2025.107983_bib115","doi-asserted-by":"crossref","first-page":"4376","DOI":"10.1073\/pnas.1616166114","article-title":"Structural basis of Tie2 activation and Tie2\/Tie1 heterodimerization","volume":"114","author":"Lepp\u00e4nen","year":"2017","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2025.107983_bib116","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/nrd.2016.278","article-title":"Therapeutic targeting of the angiopoietin-TIE pathway","volume":"16","author":"Saharinen","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2025.107983_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106331","article-title":"Role of Angiopoietin-Tie axis in vascular and lymphatic systems and therapeutic interventions","volume":"182","author":"Wang","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2025.107983_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.acthis.2024.152228","article-title":"Angiopoietins\/Tie2 signaling axis and its role in angiogenesis of psoriasis","volume":"127","author":"Li","year":"2025","journal-title":"Acta Histochem."},{"key":"10.1016\/j.phrs.2025.107983_bib119","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1083\/jcb.23.1.101","article-title":"New cytoplasmic components in arterial endothelia","volume":"23","author":"Weibel","year":"1964","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.phrs.2025.107983_bib120","first-page":"198","article-title":"How do angiopoietins tie in with vascular endothelial growth factors?","volume":"17","author":"Saharinen","year":"2010","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.phrs.2025.107983_bib121","doi-asserted-by":"crossref","first-page":"7205","DOI":"10.1073\/pnas.1216890110","article-title":"Structural basis for angiopoietin-1-mediated signaling initiation","volume":"110","author":"Yu","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2025.107983_bib122","doi-asserted-by":"crossref","first-page":"596","DOI":"10.3390\/pathophysiology31040043","article-title":"Flavonoid-mediated suppression of tumor angiogenesis: roles of ang-Tie\/PI3K\/AKT","volume":"31","author":"Saini","year":"2024","journal-title":"Pathophysiology"},{"key":"10.1016\/j.phrs.2025.107983_bib123","doi-asserted-by":"crossref","first-page":"5730","DOI":"10.3390\/cancers13225730","article-title":"Targeting Tie2 in the tumor microenvironment: from angiogenesis to dissemination","volume":"13","author":"Duran","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.phrs.2025.107983_bib124","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1186\/s12964-024-01580-3","article-title":"Ephs in cancer progression: complexity and context-dependent nature in signaling, angiogenesis and immunity","volume":"22","author":"Guo","year":"2024","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.phrs.2025.107983_bib125","doi-asserted-by":"crossref","first-page":"2462855","DOI":"10.1080\/21688370.2025.2462855","article-title":"Ephrin-Eph signaling: an important regulator of epithelial integrity and barrier function","author":"Liu","year":"2025","journal-title":"Tissue Barriers"},{"key":"10.1016\/j.phrs.2025.107983_bib126","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2022.110579","article-title":"Signals transduced by eph receptors and ephrin ligands converge on MAP kinase and AKT pathways in human cancers","volume":"104","author":"Lau","year":"2023","journal-title":"Cell Signal."},{"key":"10.1016\/j.phrs.2025.107983_bib127","doi-asserted-by":"crossref","first-page":"R90","DOI":"10.1016\/j.cub.2017.01.003","article-title":"Ephs and ephrins","volume":"27","author":"Taylor","year":"2017","journal-title":"Curr. Biol."},{"key":"10.1016\/j.phrs.2025.107983_bib128","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1110\/ps.062665807","article-title":"Crystal structure of the human ephrin-A5 ectodomain","volume":"16","author":"Nikolov","year":"2007","journal-title":"Protein Sci."},{"key":"10.1016\/j.phrs.2025.107983_bib129","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41568-023-00634-x","article-title":"Eph receptors and ephrins in cancer progression","volume":"24","author":"Pasquale","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2025.107983_bib130","doi-asserted-by":"crossref","first-page":"1275330","DOI":"10.3389\/fonc.2024.1275330","article-title":"Potential role of the eph\/ephrin system in colorectal cancer: emerging druggable molecular targets","volume":"14","author":"Scarini","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.phrs.2025.107983_bib131","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.3389\/fimmu.2019.01473","article-title":"Emerging roles for eph receptors and ephrin ligands in immunity","volume":"10","author":"Darling","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.phrs.2025.107983_bib132","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1016\/j.yexcr.2008.09.021","article-title":"Signaling from endosomes: location makes a difference","volume":"315","author":"Sadowski","year":"2009","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.phrs.2025.107983_bib133","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/nrc2806","article-title":"Eph receptors and ephrins in cancer: bidirectional signalling and beyond","volume":"10","author":"Pasquale","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.phrs.2025.107983_bib134","doi-asserted-by":"crossref","first-page":"7390104","DOI":"10.1155\/2018\/7390104","article-title":"Differential expression patterns of eph receptors and ephrin ligands in human cancers","volume":"2018","author":"Kou","year":"2018","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.phrs.2025.107983_bib135","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.3390\/ijms18081786","article-title":"A review of anti-angiogenic targets for monoclonal antibody cancer therapy","volume":"18","author":"Kong","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2025.107983_bib136","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s43556-022-00100-4","article-title":"Development of therapeutic antibodies for the treatment of diseases","volume":"3","author":"Wang","year":"2022","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.phrs.2025.107983_bib137","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/256495a0","article-title":"Continuous cultures of fused cells secreting antibody of predefined specificity","volume":"256","author":"Kohler","year":"1975","journal-title":"Nature"},{"key":"10.1016\/j.phrs.2025.107983_bib138","doi-asserted-by":"crossref","first-page":"1307860","DOI":"10.3389\/fphar.2023.1307860","article-title":"Recent advances of anti-angiogenic inhibitors targeting VEGF\/VEGFR axis","volume":"14","author":"Wang","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.phrs.2025.107983_bib139","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1080\/14712598.2021.1935231","article-title":"Up-to-date role of aflibercept in the treatment of colorectal cancer","volume":"21","author":"Saoudi Gonzalez","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.phrs.2025.107983_bib140","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41433-024-03373-x","article-title":"Exploring new horizons in neovascular age-related macular degeneration: novel mechanisms of action and future therapeutic avenues","volume":"39","author":"Shirian","year":"2025","journal-title":"Eye"},{"key":"10.1016\/j.phrs.2025.107983_bib141","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106156","article-title":"Targeting BCR-Abl in the treatment of Philadelphia-chromosome positive chronic myelogenous leukemia","volume":"178","author":"Roskoski","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2025.107983_bib142","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.phrs.2015.01.003","article-title":"Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors","volume":"94","author":"Roskoski","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2025.107983_bib143","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2015.07.010","article-title":"A historical overview of protein kinases and their targeted small molecule inhibitors","volume":"100","author":"Roskoski","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2025.107983_bib144","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107723","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2025 update","volume":"216","author":"Roskoski","year":"2025","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2025.107983_bib145","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.phrs.2015.10.021","article-title":"Classification of small molecule protein kinase inhibitors based upon the structures of their drug-enzyme complexes","volume":"103","author":"Roskoski","year":"2016","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2025.107983_bib146","doi-asserted-by":"crossref","first-page":"4841","DOI":"10.1158\/0008-5472.CAN-15-3062","article-title":"Pexmetinib: a novel dual inhibitor of Tie2 and p38 MAPK with efficacy in preclinical models of myelodysplastic syndromes and acute myeloid leukemia","volume":"76","author":"Bachegowda","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2025.107983_bib147","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1158\/1535-7163.MCT-17-0241","article-title":"The selective Tie2 inhibitor rebastinib blocks recruitment and function of Tie2 macrophages in breast cancer and pancreatic neuroendocrine tumors","volume":"16","author":"Harney","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.phrs.2025.107983_bib148","doi-asserted-by":"crossref","first-page":"4093","DOI":"10.18632\/oncotarget.6547","article-title":"Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma","volume":"7","author":"Patwardhan","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.phrs.2025.107983_bib149","doi-asserted-by":"crossref","first-page":"3713","DOI":"10.1158\/1078-0432.CCR-06-2590","article-title":"Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647","volume":"13","author":"Gendreau","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2025.107983_bib150","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s00280-023-04534-7","article-title":"Comparative biochemical kinase activity analysis identifies rivoceranib as a highly selective VEGFR2 inhibitor","volume":"91","author":"Jang","year":"2023","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.phrs.2025.107983_bib151","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.phrs.2018.01.021","article-title":"The role of small molecule platelet-derived growth factor receptor (PDGFR) inhibitors in the treatment of neoplastic disorders","volume":"129","author":"Roskoski","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2025.107983_bib152","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2017.12.021","article-title":"Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers","volume":"128","author":"Roskoski","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2025.107983_bib153","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107181","article-title":"Combination immune checkpoint and targeted protein kinase inhibitors for the treatment of renal cell carcinomas","volume":"203","author":"Roskoski","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2025.107983_bib154","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.phrs.2019.03.006","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors","volume":"144","author":"Roskoski","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2025.107983_bib155","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104567","article-title":"The role of fibroblast growth factor receptor (FGFR) protein-tyrosine kinase inhibitors in the treatment of cancers including those of the urinary bladder","volume":"151","author":"Roskoski","year":"2020","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2025.107983_bib156","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107059","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2024 update","volume":"200","author":"Roskoski","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2025.107983_bib157","doi-asserted-by":"crossref","first-page":"7787","DOI":"10.2147\/CMAR.S215533","article-title":"Fruquintinib: a novel antivascular endothelial growth factor receptor tyrosine kinase inhibitor for the treatment of metastatic colorectal cancer","volume":"11","author":"Zhang","year":"2019","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.phrs.2025.107983_bib158","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.106037","article-title":"Properties of FDA-approved small molecule protein kinase inhibitors: a 2022 update","volume":"175","author":"Roskoski","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2025.107983_bib159","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1158\/1078-0432.CCR-21-2334","article-title":"FDA approval summary: tivozanib for relapsed or refractory renal cell carcinoma","volume":"28","author":"Chang","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2025.107983_bib160","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/s41573-023-00671-z","article-title":"Targeting angiogenesis in oncology, ophthalmology and beyond","volume":"22","author":"Cao","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2025.107983_bib161","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1080\/14656566.2025.2496424","article-title":"Beyond the injection: delivery systems reshaping retinal disease management","volume":"26","author":"Rowe","year":"2025","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.phrs.2025.107983_bib162","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaapos.2025.104106","article-title":"Outcomes and comparative analysis of therapeutic approaches for choroidal neovascular membranes associated with optic nerve head drusen in pediatric patients","volume":"29","author":"Shirian","year":"2025","journal-title":"J. AAPOS"},{"key":"10.1016\/j.phrs.2025.107983_bib163","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: therapeutic implications","volume":"285","author":"Folkman","year":"1971","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2025.107983_bib164","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3390\/pharmaceutics17030394","article-title":"The 20th anniversary of pegaptanib (MacugenTM), the first approved aptamer medicine: history, recent advances and future prospects of aptamers in therapy","volume":"17","author":"Bege","year":"2025","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.phrs.2025.107983_bib165","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12959-025-00770-4","article-title":"Thromboembolic events associated with angiogenesis inhibitors: a real-world study of data from the food and drug administration adverse event reporting system (FAERS) database","volume":"23","author":"Zhou","year":"2025","journal-title":"Thromb. J."},{"key":"10.1016\/j.phrs.2025.107983_bib166","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107465","article-title":"Targeted and cytotoxic inhibitors used in the treatment of lung cancers","volume":"209","author":"Roskoski","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2025.107983_bib167","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107534","article-title":"Targeted and cytotoxic inhibitors used in the treatment of breast cancer","volume":"210","author":"Roskoski","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2025.107983_bib168","article-title":"Endothelial cell in tumor angiogenesis: origins, mechanisms, and therapeutic implication","volume":"12","author":"Han","year":"2025","journal-title":"Genes Dis."},{"key":"10.1016\/j.phrs.2025.107983_bib169","first-page":"812","article-title":"Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American society of clinical oncology","volume":"27","author":"Winer","year":"2009"},{"key":"10.1016\/j.phrs.2025.107983_bib170","first-page":"240","article-title":"Guidelines for preparing color figures for everyone including the colorblind","volume":"119","author":"Roskoski","year":"2017"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825004086?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825004086?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T04:37:35Z","timestamp":1762490255000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661825004086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":170,"alternative-id":["S1043661825004086"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2025.107983","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Vascular endothelial cells and angiogenesis","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2025.107983","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107983"}}